 |
 |
Journal articles
Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors
Abstract : Cancer immunotherapy is a rapidly evolving field that offers a novel paradigm for cancer treatment: therapies focus on enhancing the immune system's innate and adaptive anti-tumor response. Early immunotherapeutics have achieved impressive clinical outcomes and monoclonal antibodies are now integral to therapeutic strategies in a variety of cancers. However, only recently have antibodies targeting innate immune cells entered clinical development. Innate immune effector cells play important roles in generating and maintaining antitumor immunity. Antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are important innate immune mechanisms for tumor eradication. These cytolytic processes are initiated by the detection of a tumor-targeting antibody and can be augmented by activating co-stimulatory pathways or blocking inhibitory signals on innate immune cells. The combination of FDA-approved monoclonal antibodies with innate effector-targeting antibodies has demonstrated potent preclinical therapeutic synergy and early-phase combinatorial clinical trials are ongoing.
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01104938
Contributor : Laurent Jonchère <>
Submitted on : Monday, January 19, 2015 - 2:55:22 PM
Last modification on : Wednesday, March 27, 2019 - 4:51:30 PM
Contributor : Laurent Jonchère <>
Submitted on : Monday, January 19, 2015 - 2:55:22 PM
Last modification on : Wednesday, March 27, 2019 - 4:51:30 PM